TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01413152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood and semen sampling, specific biological exams and biobank and self administered questionnaires
Description: blood and semen sampling, specific biological exams and biobank and self administered questionnaires
Study: NCT03456973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse AMIE
Description: Supportive care software platform
Study: NCT01339000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycosylated Recombinant Human Interleukin-7
Description: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycosylated Recombinant Human Interleukin-7
Description: Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria/Tetanus Vaccine
Description: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria/Tetanus Vaccine
Description: Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Vaccine
Description: Polio Vaccine will be administered according to the randomized schedule per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Vaccine
Description: Polio Vaccine will be administered according to the randomized schedule per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: Hepatitis B vaccine will be administered according to the randomization schedule per protocol.
Study: NCT00741117

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial Blood Gas
Description: One blood gas sample will be obtained from an artery in the arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial Blood Gas
Description: One blood gas sample will be obtained from an artery in the arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial Blood Gas
Description: One blood gas sample will be obtained from an artery in the arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Oximetry Machine
Description: A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Oximetry Machine
Description: A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Oximetry Machine
Description: A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct and Indirect Serum Bilirubin Measurement
Description: One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct and Indirect Serum Bilirubin Measurement
Description: One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct and Indirect Serum Bilirubin Measurement
Description: One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.
Study: NCT04626882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staged in-hospital or Immediate complete revascularization
Description: Patients with ST-segment elevation myocardial infarction and multivessel disease will be randomized after primary PCI for IRA. All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged in-hospital or Immediate complete revascularization
Description: Patients with ST-segment elevation myocardial infarction and multivessel disease will be randomized after primary PCI for IRA. All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Study: NCT01387360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supracor
Description: The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision.~The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances.
Study: NCT03422796

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cilostazol 200mg
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 200mg
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUMAtriptan 6 MG/ML
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study: NCT03974516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Careseng 1370
Description: Careseng 1370 should be taken around 1 hour before meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Careseng 1370
Description: Careseng 1370 should be taken around 1 hour before meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Careseng 1370
Description: Careseng 1370 should be taken around 1 hour before meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Careseng 1370
Description: Careseng 1370 should be taken around 1 hour before meal.
Study: NCT03735095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfimer Sodium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy
Description: Undergo EBUS-TBN guided I-PDT
Study: NCT03692286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide Intracanal medication
Description: Calcium hydroxide intracanal medication
Study: NCT04255576

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Calcium/Vitamin D
Description: All subjects should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
Study: NCT00101270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT02442947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clothing type, protective garments of Paul Boye Technologies
Description: The experiment aimed at evaluating the physiological stress obtained when dressed in different clothing (NBC protective garment \[charcoal base\], combat garment and 2 different types of work uniforms- (1)50% cotton and 50% polyester (2)80% cotton and 20% polyester) and during exertion under heat conditions.
Study: NCT03671161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Pump and flash glucose monitoring
Description: Adults with type 1 diabetes, HbA1c \>9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day. Patients will be switched to insulin pump and start a FGM system (Free Style Libre®) during 6 months.
Study: NCT04653038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD013
Description: A fixed dose of MGD013 600mg IV Q2W will be administered to subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD013
Description: A fixed dose of MGD013 600mg IV Q2W will be administered to subjects
Study: NCT01870687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg VAC BNO 1095 FCT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01161706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable Juice
Description: Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable Juice
Description: Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.
Study: NCT01902017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg placebo PO bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg placebo PO bid
Study: NCT01982916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for AGR tablet and/or Active Comparator)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for AGR tablet and/or Active Comparator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for AGR tablet and/or Active Comparator)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Study: NCT01411189

Intervention type: DRUG
Group type: OTHER
Intervention: Menthol
Description: 20 mL NPO-11 in prefilled syringe
Study: NCT01033747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 10 mg/kg or 30 mg/kg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 5 mg/kg or 30 mg/kg orally daily
Study: NCT01431066

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham pulsed radio-frequency electromagnetic device
Description: Disabled PRFE device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiPatch PRFE Device
Description: Actipatch PRFE device
Study: NCT02940470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie restricted diet plus exercise
Description: Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight management classes
Description: Weekly 1-hour weight management classes for 12 weeks.
Study: NCT02306915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipegfilgrastim
Description: lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipegfilgrastim
Description: lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipegfilgrastim
Description: lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
Study: NCT03575130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripasudil eye drops
Description: Rho-kinase-Inhibitor (IMP)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optive eye drops
Description: Artificial tears (placebo)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Descemetorhexis
Description: Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Descemetorhexis
Description: Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
Study: NCT00003498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02881281

Intervention type: OTHER
Group type: OTHER
Intervention: educational program for Development of problem-solving skills

Intervention type: OTHER
Group type: OTHER
Intervention: no education program
Description: no education program
Study: NCT00701389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant potassium
Description: Single oral dose of 2 x 300 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant potassium
Description: Single oral dose of 2 x 300 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant potassium
Description: Single oral dose of 2 x 300 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant potassium
Description: Single oral dose of 2 x 300 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan
Description: single oral dose of 100 mg sumatriptan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan
Description: single oral dose of 100 mg sumatriptan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan
Description: single oral dose of 100 mg sumatriptan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan
Description: single oral dose of 100 mg sumatriptan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan placebo
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan placebo
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan placebo
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan placebo
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant potassium placebo
Description: single oral dose of 2 MK-0974 placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant potassium placebo
Description: single oral dose of 2 MK-0974 placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant potassium placebo
Description: single oral dose of 2 MK-0974 placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant potassium placebo
Description: single oral dose of 2 MK-0974 placebo capsules
Study: NCT01055639

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person ACT
Description: 8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth ACT
Description: 8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
Study: NCT03324061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant for Injectable Suspension
Description: Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faslodex (Reference)
Description: Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas
Study: NCT04077008

Intervention type: PROCEDURE
Group type: OTHER
Intervention: unilateral drainage of Bilaterally Obstructed Kidneys
Description: drainage of obsructed kidneys by PCN or jj

Intervention type: PROCEDURE
Group type: OTHER
Intervention: unilateral drainage of Bilaterally Obstructed Kidneys
Description: drainage of obsructed kidneys by PCN or jj

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bilateral drainage of Bilaterally Obstructed Kidneys
Description: drainage of obsructed kidneys by PCN or jj

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bilateral drainage of Bilaterally Obstructed Kidneys
Description: drainage of obsructed kidneys by PCN or jj
Study: NCT03567239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using adaptive device.
Description: Participant uses the specially designed device for a specified length of time (no less than two days) and feedback is then gathered from the participant through questionnaires. These questionnaires include NASA-TLX, PIADS, QUEST, and a single question asking if the device improved their ability to address their specific need.
Study: NCT03810742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan
Description: Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
Study: NCT02767557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravenous infusion
Study: NCT00472199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00138645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MicroDiet
Description: MicroDiet
Study: NCT02767557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: Intravenous infusion,
Study: NCT02010385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT03864900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The medication adherence intervention
Description: The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
Study: NCT02767557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Intravenous infusion,
Study: NCT01194232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 8 week course of Sildenafil administered at a dose of 1 mg / Kg three times a day with a maximum dose of 20 mg per dose.
Study: NCT02352571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1118
Description: For Part A, GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in the dose escalation cohorts, starting 0.3mg/kg until Maximum Tolerated Dose is defined.~For Part B, the defined MTD/RP2D of GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in patients with stage IV of gastric cancer, colorectal cancer or other cancers.~For Part C, GC1118 will be administered by IV infusion once every 2 weeks for 4 weeks (28-day cycles) in patients with all stage IV advanced solid cancers.~Part A, Part B and Part C participants who qualify for subsequent cycles will receive continued GC1118 until evidence of progression of disease.
Study: NCT01963546

Intervention type: OTHER
Group type: OTHER
Intervention: different types of anesthesia

Intervention type: OTHER
Group type: OTHER
Intervention: different types of anesthesia

Intervention type: OTHER
Group type: OTHER
Intervention: different types of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: After selecting the appropriate anesthesia method, assess the effect of dexmedetomidine on controlling stress response from diabetics undergoing laparoscopic gastric-bypass surgical.The stress indicators are the same as described above.
Study: NCT03627546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Treatment strategy
Description: The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during 12 weeks of provided sofusbuvir/velpatasvir treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (facilitated referral)
Description: articipants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then followed separately. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.